Next Article in Journal
Coming of Age for Autotaxin and Lysophosphatidate Signaling: Clinical Applications for Preventing, Detecting and Targeting Tumor-Promoting Inflammation
Next Article in Special Issue
Immunohistochemistry for Diagnosis of Metastatic Carcinomas of Unknown Primary Site
Previous Article in Journal
Proton Beam Therapy without Fiducial Markers Using Four-Dimensional CT Planning for Large Hepatocellular Carcinomas
Previous Article in Special Issue
Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessFeature PaperReview
Cancers 2018, 10(3), 72; https://doi.org/10.3390/cancers10030072

Update on Immunohistochemistry for the Diagnosis of Lung Cancer

Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan
Received: 3 February 2018 / Revised: 9 March 2018 / Accepted: 13 March 2018 / Published: 14 March 2018
(This article belongs to the Special Issue Immunohistochemistry and Cancer Diagnosis)
  |  
PDF [8021 KB, uploaded 14 March 2018]
  |  

Abstract

Immunohistochemistry is a widely available technique that is less challenging and can provide clinically meaningful results quickly and cost-efficiently in comparison with other techniques. In addition, immunohistochemistry allows for the evaluation of cellular localization of proteins in the context of tumor structure. In an era of precision medicine, pathologists are required to classify lung cancer into specific subtypes and assess biomarkers relevant to molecular-targeted therapies. This review summarizes the hot topics of immunohistochemistry in lung cancer, including (i) adenocarcinoma vs squamous cell carcinoma; (ii) neuroendocrine markers; (iii) ALK, ROS1, and EGFR; (iv) PD-L1 (CD274); (v) lung carcinoma vs malignant mesothelioma; and (vi) NUT carcinoma. Major pitfalls in evaluating immunohistochemical results are also described. View Full-Text
Keywords: immune checkpoint; immunostaining; INSM1; morphology; non-small cell lung carcinoma (NSCLC); pathology; thoracic tumor; small cell lung carcinoma (SCLC); tyrosine kinase; WHO classification immune checkpoint; immunostaining; INSM1; morphology; non-small cell lung carcinoma (NSCLC); pathology; thoracic tumor; small cell lung carcinoma (SCLC); tyrosine kinase; WHO classification
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Inamura, K. Update on Immunohistochemistry for the Diagnosis of Lung Cancer. Cancers 2018, 10, 72.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top